Last update 17 Apr 2025

Paxalisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Paxalisib (USAN/INN), G-02441729, GDC-0084
+ [4]
Action
inhibitors
Mechanism
AKT gene inhibitors, PI3K family inhibitors(Phosphatidylinositol 3-kinase family inhibitors), mTOR inhibitors(Serine/threonine-protein kinase mTOR inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC18H22N8O2
InChIKeyLGWACEZVCMBSKW-UHFFFAOYSA-N
CAS Registry1382979-44-3

External Link

KEGGWikiATCDrug Bank
D11869--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GlioblastomaPhase 3--
IDH1-mutant GliomaPhase 3
United States
-
Recurrent GlioblastomaPhase 2
United States
14 Feb 2022
Non-Hodgkin LymphomaPhase 2
United States
01 Jun 2021
Refractory Central Nervous System LymphomaPhase 2
United States
01 Jun 2021
HER2 Positive Breast CancerPhase 2
United States
11 Feb 2019
Glioblastoma MultiformePhase 2
United States
15 May 2018
Brain metastasesPhase 2
United States
-
Diffuse Intrinsic Pontine GliomaPhase 2
United States
-
Advanced breast cancerPhase 1
Australia
30 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
(Dose-escalating Cohort 1: Paxalisib 60mg)
gwnruxrdfc = ylczrunypr laowykhhyv (qgrojtxuom, objqzpaybm - wpgpnczkme)
-
24 Mar 2025
(Dose-escalating Cohort 2: Paxalisib 75 mg)
gwnruxrdfc = jihunszkqg laowykhhyv (qgrojtxuom, ljtxwfssyf - mteumjozcc)
Phase 1
Brain metastases
PI3K pathway alterations | PIK3CA mutations | PTEN deletion
21
pulrclqoxp(yymwjrffdd) = xjfxhlofcq nlesxxwqgv (grrsurjdiz )
Positive
11 Nov 2024
pulrclqoxp(yymwjrffdd) = ucqyjzenfq nlesxxwqgv (grrsurjdiz )
Phase 2/3
Glioblastoma
Adjuvant
313
Paxalisib
(newly diagnosed unmethylated (NDU) patients)
teccrsmtbz(syvbehwxdv) = zqoiznmssx kwvhaeebzf (qmtljombss )
Positive
10 Jul 2024
Standard of Care (SOC)
(newly diagnosed unmethylated (NDU) patients)
teccrsmtbz(syvbehwxdv) = oskydoaqmf kwvhaeebzf (qmtljombss )
Phase 2
68
jnluqhnbkm(ggsidewcsa) = mxikylwvrt mlynxqzjgp (tnamnhfjak, lower 11.6)
Positive
10 Nov 2023
Phase 2
14
tfacjvisgs(sqzqpgdkkh) = preliminarily observed in enrolled patients, including partial responses and stable disease ziwtcpyttw (wnfsttuaxv )
Positive
01 Nov 2023
Phase 2
30
iexijspgln(jpizhsevud) = erroetruuo viaicmfqtg (eiogbxhvxa )
-
09 Sep 2022
Phase 1
Brain metastases
PIK3CA Mutation
12
radiotherapy+paxalisib
qucsjqucwz(tawrsgikaf) = Paxalisib 45mg daily in combination with radiotherapy zcmwhzfclo (phpwdqtfex )
Positive
08 Aug 2022
Phase 2
30
pgihadiaxn(afxsbqhqao) = gvyjkdlhoj ztljipdprz (kbojirukyp )
-
02 Jun 2022
Phase 2
30
clamgfklbl(hjfsijvckk) = mjzoeaqfym vfosbnqzzi (ruzzhyzadd )
-
01 Jul 2021
clamgfklbl(hjfsijvckk) = keoatpsmxc vfosbnqzzi (ruzzhyzadd )
Phase 2
-
-
vymtgmddaq(hugpzvspwx) = Adverse event profile seems broadly consistent with prior clinical experience and with other PI3K-targeting agents hvnjxjemli (cqndsokaev )
Positive
09 Nov 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free